PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data

Completed

Conditions: Non-valvular Atrial Fibrillation

Interventions: Drug: Warfarin
Drug: Apixaban

First Posted Date: 2022-06-30

Last Posted Date: 2024-05-20

Lead Sponsor: Pfizer

Target Recruit Count: 77814

Registration Number: NCT05438888

Locations: 🇯🇵
Pfizer Site, Tokyo, Japan

A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: Nirmatrelvir
Drug: Ritonavir
Drug: Placebo for nirmatrelvir
Drug: Placebo for ritonavir

First Posted Date: 2022-06-30

Last Posted Date: 2024-01-25

Lead Sponsor: Pfizer

Target Recruit Count: 157

Registration Number: NCT05438602

Locations: 🇨🇦
Diex Recherche Sherbrooke Inc., Sherbrooke, Quebec, Canada
🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇧🇷
IBPClin - Instituto Brasil de Pesquisa Clínica, Rio de Janeiro, Brazil

and more 79 locations

A First-In-Human Study of the Study Medicine, Called PF-07291177, in Healthy Adult Participants

Phase 1

Withdrawn

Conditions: Healthy Participants

Interventions: Drug: PF-07291177
Drug: Placebo

First Posted Date: 2022-06-27

Last Posted Date: 2022-09-07

Lead Sponsor: Pfizer

Registration Number: NCT05434091

A Study to Investigate the Effect of Tablet Formulation and Food on PF-07104091 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Single dose of PF-07104091 as Tablet Formulation A (Treatment A)
Drug: Single dose of PF-07104091 as Tablet Formulation B (Treatment B)
Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment C)
Drug: Single dose of PF-07104091 as Tablet Formulation D (Treatment D)
Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment E)

First Posted Date: 2022-06-24

Last Posted Date: 2024-04-08

Lead Sponsor: Pfizer

Target Recruit Count: 30

Registration Number: NCT05431153

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

A Phase 2/3 Study in Adult and Pediatric Participants With SCD

Phase 2

Active, not recruiting

Conditions: Sickle Cell Disease

Interventions: Drug: Osivelotor

First Posted Date: 2022-06-24

Last Posted Date: 2024-11-11

Lead Sponsor: Pfizer

Target Recruit Count: 429

Registration Number: NCT05431088

Locations: 🇺🇸
LSU Health Baton Rouge-North Clinic, Baton Rouge, Louisiana, United States
🇺🇸
Our Lady of the Lake Hopistal, Inc, Baton Rouge, Louisiana, United States
🇺🇸
Our lady of the Lake Hospital, Baton Rouge, Louisiana, United States

and more 44 locations

Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy

Phase 2

Active, not recruiting

Conditions: Muscular Dystrophy, Duchenne

Interventions: Genetic: PF-06939926

First Posted Date: 2022-06-23

Last Posted Date: 2024-04-04

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT05429372

Locations: 🇺🇸
UF Health Shands Hospital, Gainesville, Florida, United States
🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇦🇺
The Children's Hospital at Westmead, Westmead, New South Wales, Australia

and more 9 locations

A Study to Learn How the Study Medicine Called PF-07275315 Works in Healthy People

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Placebo
Drug: PF-07275315

First Posted Date: 2022-06-09

Last Posted Date: 2024-06-03

Lead Sponsor: Pfizer

Target Recruit Count: 65

Registration Number: NCT05411588

Locations: 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

and more 1 locations

A Study to Learn About Sickle Cell Disease In Adult Patients

Completed

Conditions: Sickle Cell Disease

Interventions: Other: Electronic Diary

First Posted Date: 2022-06-07

Last Posted Date: 2024-07-16

Lead Sponsor: Pfizer

Target Recruit Count: 98

Registration Number: NCT05407805

Locations: 🇺🇸
Mid-Atlantic Permanente Medical Group Largo Medical Center, Upper Marlboro, Maryland, United States
🇺🇸
Sanguine Biosciences, Inc., Waltham, Massachusetts, United States
🇺🇸
Cohen Children's Medical Center, New Hyde Park, New York, United States

and more 1 locations

Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13

Phase 3

Completed

Conditions: Pneumococcal Disease

Interventions: Biological: 20-valent pneumococcal conjugate vaccine
Biological: 13-valent pneumococcal conjugate vaccine

First Posted Date: 2022-06-07

Last Posted Date: 2023-11-03

Lead Sponsor: Pfizer

Target Recruit Count: 356

Registration Number: NCT05408429

Locations: 🇭🇺
Lurko-Med Kft Hazi Gyermekorvosi Rendelo, Budapest, Hungary
🇵🇱
IN-VIVO Bydgoszcz, Bydgoszcz, Poland
🇵🇱
Uniwersytecki Szpital Kliniczny im. J. Mikulicza-Radeckiego we Wroclawiu, Wroclaw, Poland

and more 33 locations

Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

Active, not recruiting

Conditions: Breast Cancer

First Posted Date: 2022-06-01

Last Posted Date: 2024-07-15

Lead Sponsor: Pfizer

Target Recruit Count: 688

Registration Number: NCT05399329

Locations: 🇯🇵
Japan Community Health care Organization Kurume General Hospital, Kurume-city, Fukuoka, Japan
🇯🇵
Tohoku University Hospital, Sendai, Miyagi, Japan
🇯🇵
Osaka International Cancer Institute, Osaka-shi, Osaka, Japan

and more 17 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy